Astellas Pharma Inc logo

Astellas Pharma Inc

ALPMY · OTC · Pharmaceuticals, Biotech · Founded 1923

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Current Price
$16.12
Market Cap
$29.2B
Return Since Last Split
+43%
Last Split
Apr 2, 2014
Total Splits
2
Cumulative Multiple
5×

What If You Bought ALPMY Earlier?

Investment
Purchase Date (Before Split)
Worth Today
$8,060
500 shares · 5×

Estimate based on split history only. Excludes dividends, fees, taxes, and intraday movement.

Stock Split History

Newest split first. Cumulative multiple = compounded growth within the displayed company lineage.

Split DatePrice BeforeRatioSplit MultipleCumulative
Apr 2, 2014$11.695-for-41.25×5×
May 13, 2013$11.234-for-14×4×

Astellas Pharma Inc Market Cap Timeline

Market capitalization from public listing to today. Split markers cover 2 current-security splits. Filled dots have market-cap data for that year; hollow dots mark split years outside market-cap source coverage.

Frequently Asked Questions

Astellas Pharma Inc's latest record in the split calendar is a 5-for-4 forward split effective 2014-04-02.
Stay in the loop

Never Miss a Stock Split Again

Get personalized stock split alerts. Choose what you receive and how often.

Your email is securely stored. We’ll only contact you about updates you choose. Unsubscribe anytime.